

CHAIR'S KEY ISSUES

ISSUES FOR REFERRING / ESCALATING TO BOARD / COMMITTEE / TASK & FINISH GROUP

ORIGINATING BOARD / COMMITTEE / TASK & FINISH GROUP: Finance & Performance Assurance Committee DATE OF MEETING ISSUE RAISED CHAIR: Julie Parker, Non-Executive Director LEAD EXECUTIVE DIRECTOR:		DATE OF MEETING ISSUE RAISED:	31 October 2019		
		Julie Parker, Non-Executive	LEAD EXECUTIVE DIRECTOR:	Director of Finance	
Agenda Item No.	DETAILS OF ISSUE:			FOR APPROVAL / ESCALATION / ALERT/ ASSURANCE / INFORMATION ?	Board o Director Update
6, 7	Finance and CIP Reports As at the end of September, the Trust is £4.5r (£9.2m). Drivers of this continue to be shortfall of junior doctors. Capital is underspent against plat the front entrance project. Risks and opportunities – the overall Trust foreout to mitigate this through local discussions with C recovery plans within the division, as well as new Cost Improvement Programme - CIP delivery is £ £16.9m against the £31.9m target, a shortfall of £ highlighted an issue on Apprenticeship Levy not Committee asked to be taken to People and C approach to apprenticeships across the entire w	on CIP delivery, under perform in year to date by £7.9m beca cast remains at an adverse va commissioners. The forecast w stretch targets for the division £8.0m behind plan year to date 15.0m. Pipeline schemes of a being fully utilised within the r Organisational Development	nance on specialist income and overspend ause of a change in timing of costs incurre ariance against control total of £9.4m with includes assumptions on the delivery of £ ons of £4.0m. e and the Trust is currently forecasting to d further £3.0m are being developed. Discus required timescales and therefore lost whic	ds on ed on plans 24.5m eliver sions th the	
8	Performance ED Economy performance - for September 2 performance was 87.92% in September, which trajectory, and the National Standard of 95%. Ris opened with effect from 1 st October 2019 and th Cancer performance - 62 Day Cancer Waits for 73.7% this is 12.8% below the trajectory of 86.5° RTT – September 2019 current RTT position wa no 52+-week breaches for September 2019. Lev	019 was 90.16% for Colche n was a deterioration on Aug k to delivery due to bed occup e impact on performance is en r 1st Treatment remains belor % and below the 85% Nationa as 82.2%. This is below the tra	gust's performance of 90.27%; below bot ancy. The new Urgent Treatment Centre se incouraging. w Target. Performance for September 20 al standard. ajectory set of 86.8% for the month. There	NEFT Assurance and h the Escalation ervice	

need to address waiting time impacts.

Agenda Item No.	DETAILS OF ISSUE:	FOR APPROVAL / ESCALATION / ALERT/ ASSURANCE / INFORMATION ?	Board of Directors Update
	Discussion highlighted the need to manage the risk of the waiting list in terms of clinical priorities and the Committee asked for this to be taken to Quality and Patient Safety (QPS).	Escalation to QPS	
	Work continues to develop community metrics; paper shared to review and discuss progress and future direction.		
9	Medium Term Financial Planning including 2020/21 Control Total		
	As part of the NHS Long Term Plan Implementation Framework, STP / ICS systems are due to submit five year strategic plans, covering finance, workforce and activity, by November 2019 that describe how they will achieve the Plan's commitments.	Information and Escalation	
	Current gap against £31.9m deficit control total for this Trust is estimated to be £4.5m but work is underway to reduce this further on a system wide basis, particularly focussing on outpatients. A 0.5% contribution (based on turnover) has been applied to East of England organisations to support a regional contingency. For ESNEFT, this is £4m. The Committee discussed the assumptions underpinning the current projections and the risks associated with those.		
	Final submission paper to go to Board in November. Submission to NHSI/E by 15/11/19.		
11	Financial Governance 2020/21		
	A paper on proposed revised Financial Governance arrangements to reflect the size of the Trust and the need for some decision making to work in a more devolved way was discussed. A Capital Planning Group could replace the Trust Investment Group to focus on assurance on management and delivery of the Trust's capital programme and driving innovation through capital investment.	Information	
	This was considered as a discussion paper and Committee comments were made with pros and cons discussed. Further work is required.		
12	Capital Plan Update		
	There is a cumulative underspend of £7.9m against planned delivery of the 2019/20 £32.2m capital programme year to date. Following the reinstatement nationally of the 20% reduction in capital plans previously required, the Trust has identified £5.9m of new schemes for the plan this year. A revised plan is to be presented to the board.	Escalation	
	The planned capital programme for 2020/21 is £41.8m (currently in the early stages of planning).		
13	BAF risk- Deep Dive into Waiting List. Deferred.		

Agenda Item No.	DETAILS OF ISSUE:	FOR APPROVAL / ESCALATION / ALERT/ ASSURANCE / INFORMATION ?	Board of Directors Update
14, 15, 16	 Other matters noted by the Committee: Key Developments in the delivery of the Ipswich and East Suffolk Alliance and Strategy Plan. Progress against the ten programmes overseen by Time Matters Board. Update on Theatre Productivity. 	Information	
DATE C	OMPLETED AND FORWARDED TO SEC OF RECEIVING BOARD / COMMITTEE / TASK & FINISH GROUP:TBC		